Skip to main content
B

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,650 across all filing types
Latest filing 2026-04-22 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2025年年度审计报告
Audit Report / Information Classification · 1% confidence The document is titled “审计报告及财务报表” for the 2025 fiscal year and contains the auditor’s opinion, key audit matters, responsibilities and the complete set of audited financial statements. It does not include narrative sections typical of a full Annual Report (10-K) or MD&A, nor is it merely an announcement. It is a standalone audit report with financial statements, matching the Audit Report / Information category.
2026-04-22 Chinese
2025年度独立董事述职报告（肖佳佳）
Governance Information Classification · 1% confidence The document is titled “2025年度独立董事述职报告” and consists of the independent director’s formal annual performance and governance duties report, including attendance at board and committee meetings, oversight activities, independence confirmations, and key governance matters. This is not a full annual report, earnings release, proxy statement, or management discussion; rather, it is a standalone governance disclosure related to board structure, director responsibilities, and compliance with corporate governance rules. Therefore, it best fits the Governance Information category (CGR).
2026-04-22 Chinese
关于“质量回报双提升”行动方案的进展公告
Regulatory Filings Classification · 1% confidence The document is a Chinese "进展公告" (progress announcement) of an ongoing “quality return double improvement” action plan by a listed pharmaceutical company, outlining pipeline updates, financial metrics, governance changes, and dividend policy. It is not a formal annual or interim report, not an earnings release, nor a financing, M&A, or other specialized filing. It is a general regulatory announcement of company operations and progress, which falls into the fallback “Regulatory Filings” category.
2026-04-22 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 1% confidence The document is titled '2026年第一季度报告' (2026 First Quarter Report) for Betta Pharmaceuticals. It contains comprehensive financial statements (Balance Sheet, Income Statement) and management's discussion of financial results for the first quarter of 2026. It is a full quarterly report, not an announcement or a summary, and it contains substantive financial data. Q1 2026
2026-04-22 Chinese
关于使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 1% confidence The document is an official company announcement detailing a board resolution to use up to RMB 1 billion of idle self-owned funds for cash management investments. It is not reporting full financial results, not a regulatory filing attachment announcement, nor a management change or share issuance. The content focuses on corporate treasury and capital use decisions, matching the Capital/Financing Update (CAP) category.
2026-04-22 Chinese
中信证券股份有限公司关于贝达药业股份有限公司使用暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 1% confidence The document is an opinion letter by the sponsor (中信证券) reviewing 贝达药业’s use of temporarily idle raised funds for cash management. It is a compliance/regulatory announcement rather than a financial report (10-K, IR), earnings release, management discussion, or shareholder vote. It does not announce an upcoming report (RPA), is not a call transcript, nor a specific transaction category like share issue or dividends. It is a routine regulatory disclosure required by the exchange, so it falls under the general “Regulatory Filings” category (RNS).
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.